Back to search results

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

ER+ HER2- Advanced Breast Cancer · High-grade Serous Ovarian Cancer (HGSOC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Research Site, St Louis, Missouri, United States

  • Research Site, Providence, Rhode Island, United States

  • Research Site, Nashville, Tennessee, United States

  • Research Site, Houston, Texas, United States

  • Research Site, East Melbourne, Australia

  • Research Site, Seoul, South Korea

  • Research Site, Seoul, South Korea

  • Research Site, Barcelona, Spain

  • Research Site, Pamplona, Spain

  • Research Site, Valencia, Spain

  • Research Site, Cambridge, United Kingdom

  • Research Site, Leeds, United Kingdom

  • Research Site, London, United Kingdom

  • Research Site, Manchester, United Kingdom

Study leads

  • Richard Baird, MD, PhD

    Study Chair

    Cambridge University Hospitals

View source on ClinicalTrials.gov(opens in a new tab)